Insider Buying Frenzy at AirSculpt Technologies
The latest filing from owner Chernett Jorey shows a fresh purchase of 77,702 shares at an average price of $2.64, bringing his holdings to 6,753,761 shares. This transaction comes on the back of a rapid, week‑long buying spree that saw Jorey accumulate roughly 400,000 shares in the first half of March alone. The cumulative outlay—approximately $2.0 million—signals a strong conviction that the stock is undervalued at its current $2.79 close, especially given the company’s 30‑week rally to a 52‑week high of $12.
What This Means for Investors
The pattern of aggressive purchases over a short period is a bullish signal, suggesting that insiders believe the AirSculpt pipeline is about to unlock significant upside. The company’s health‑care niche—custom body contouring—has been gaining traction, and the recent price movement hints at broader market enthusiasm. However, the negative P/E of –9.1 and the company’s thin earnings buffer remind investors to tread carefully; insider optimism does not eliminate the risk of a correction if clinical or regulatory milestones fail to materialise.
Chernett Jorey: A Consistent Buyer
Jorey’s transaction history over the past year shows a steady, disciplined buying approach: average purchase prices ranging from $1.71 to $2.70, with volumes clustering around 80,000–105,000 shares per trade. Unlike sporadic “big‑ticket” trades, his actions reflect a long‑term stake‑holding strategy rather than short‑term speculation. This consistency suggests he views AirSculpt as a growth vehicle rather than a quick‑turn play.
Company‑Wide Insider Activity
Beyond Jorey, the company’s executive team has displayed mixed behaviour: the CEO sold 24,217 shares in February, while the CFO’s purchase of 147,059 shares in January was at zero cost, presumably through a grant or vesting event. The absence of large sell‑side transactions in recent weeks indicates that senior leadership remains invested in AirSculpt’s trajectory.
Bottom Line
For investors watching AirSculpt, Jorey’s continued buying spree—and the broader insider confidence—offers a potential catalyst for the stock. Yet the company’s modest valuation metrics and the highly specialised nature of its services mean that any upside will likely depend on successful commercialization and expansion beyond the U.S. market. Keeping an eye on upcoming earnings, regulatory filings, and any new product launches will be key to assessing whether insider enthusiasm translates into sustainable shareholder returns.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-03-19 | Chernett Jorey () | Buy | 77,702.00 | 2.64 | Common Stock |
